ReviewHematology/oncology clinics of North America2014
Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.
Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 79 citations in OpenAlex.
- Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease.American journal of hematology · 2025Trial
- Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.British journal of clinical pharmacology · 2019Trial
- Dissolved Oxygen-Dependent Magnetophoresis of Sickle Red Blood Cells and Proof-of-Concept Separation Using a Magnetic Column.ACS measurement science au · 2026Article
- Loss of energy homeostasis contributes to hepatic damage development in sickle cell disease.Molecular metabolism · 2026Article
- 2,3-Diphosphoglycerate: the forgotten metabolic regulator of oxygen affinity.The British journal of nutrition · 2025Review
- HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity.Cell · 2025Article
- Hypoxia as a medicine.Science translational medicine · 2025Review
- Hemoglobin Variants as Targets for Stabilizing Drugs.Molecules (Basel, Switzerland) · 2025Review
- Metabolic regulation of erythrocyte development and disorders.Experimental hematology · 2024Article
- Targeted modification of furan-2-carboxaldehydes into Michael acceptor analogs yielded long-acting hemoglobin modulators with dual antisickling activities.Chemical biology & drug design · 2024Article
- Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation.Biophysical journal · 2023Article
- Quantitative assessment of the in-vitro binding kinetics of antisickling aromatic aldehydes with hemoglobin A: A universal HPLC-UV/Vis method to quantitate Schiff-base adduct formation.Journal of pharmaceutical and biomedical analysis · 2023Article
- Peak nasal inspiratory flow in children and adolescents with sickle cell disease: a case-control study.Revista da Associacao Medica Brasileira (1992) · 2023Article
- X-ray crystallography and sickle cell disease drug discovery-a tribute to Donald Abraham.Frontiers in molecular biosciences · 2023Review
- Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives.Journal of blood medicine · 2023Review
- The oxygen dissociation curve of blood in COVID-19-An update.Frontiers in medicine · 2023Review
- Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Aromatic Aldehydes as Drug Candidates for the Treatment of Sickle Cell Disease.Molecules (Basel, Switzerland) · 2022Article
- Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.International journal of molecular sciences · 2022Review
- Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.Expert opinion on therapeutic patents · 2022Review
- Drug discovery by a basic research scientist.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The pathophysiology of sickle cell disease involves the polymerization of sickle hemoglobin in its T state, which develops under low oxygen saturation. One therapeutic strategy is to develop pharmacologic agents to stabilize the R state of hemoglobin, which has higher oxygen affinity and is expected to have slower kinetics of polymerization, potentially delaying the sickling of red cells during circulation. This strategy has stimulated the investigation of aromatic aldehydes, aspirin derivatives, thiols, and isothiocyanates that can stabilize the R state of hemoglobin in vitro. One representative aromatic aldehyde agent, 5-hydoxymethyl-2-furfural, protects sickle cell mice from the effects of hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.